Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA253717
Max Phase: Preclinical
Molecular Formula: C25H33ClN4
Molecular Weight: 389.57
Molecule Type: Small molecule
Associated Items:
ID: ALA253717
Max Phase: Preclinical
Molecular Formula: C25H33ClN4
Molecular Weight: 389.57
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CCN(CC)CCCC(C)Nc1c2ccccc2[n+](C)c2c1[nH]c1ccccc12.[Cl-]
Standard InChI: InChI=1S/C25H32N4.ClH/c1-5-29(6-2)17-11-12-18(3)26-23-20-14-8-10-16-22(20)28(4)25-19-13-7-9-15-21(19)27-24(23)25;/h7-10,13-16,18H,5-6,11-12,17H2,1-4H3,(H,26,27);1H
Standard InChI Key: KVDZSQVEWLLVGB-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 389.57 | Molecular Weight (Monoisotopic): 389.2700 | AlogP: 5.22 | #Rotatable Bonds: 8 |
Polar Surface Area: 34.94 | Molecular Species: BASE | HBA: 2 | HBD: 2 |
#RO5 Violations: 1 | HBA (Lipinski): 4 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: 9.78 | CX Basic pKa: 10.47 | CX LogP: -0.59 | CX LogD: -2.65 |
Aromatic Rings: 4 | Heavy Atoms: 29 | QED Weighted: 0.41 | Np Likeness Score: -0.13 |
1. Lavrado J, Paulo A, Gut J, Rosenthal PJ, Moreira R.. (2008) Cryptolepine analogues containing basic aminoalkyl side-chains at C-11: synthesis, antiplasmodial activity, and cytotoxicity., 18 (4): [PMID:18207399] [10.1016/j.bmcl.2008.01.015] |
2. Lavrado J, Reszka AP, Moreira R, Neidle S, Paulo A.. (2010) C-11 diamino cryptolepine derivatives NSC748392, NSC748393, and NSC748394: anticancer profile and G-quadruplex stabilization., 20 (23): [PMID:20952194] [10.1016/j.bmcl.2010.09.110] |
3. Lavrado J, Cabal GG, Prudêncio M, Mota MM, Gut J, Rosenthal PJ, Díaz C, Guedes RC, dos Santos DJ, Bichenkova E, Douglas KT, Moreira R, Paulo A.. (2011) Incorporation of basic side chains into cryptolepine scaffold: structure-antimalarial activity relationships and mechanistic studies., 54 (3): [PMID:21207937] [10.1021/jm101383f] |
4. Lavrado J, Mackey Z, Hansell E, McKerrow JH, Paulo A, Moreira R.. (2012) Antitrypanosomal and cysteine protease inhibitory activities of alkyldiamine cryptolepine derivatives., 22 (19): [PMID:22926067] [10.1016/j.bmcl.2012.07.104] |
Source(1):